Tofacitinib citrate is the active pharmaceutical ingredient (API) used in the medication tofacitinib [1]. Tofacitinib is a Janus kinase (JAK) inhibitor that works by blocking the activity of certain enzymes involved in the immune response [2]. This action helps to reduce inflammation [2].
What is tofacitinib citrate used for?
Tofacitinib citrate is approved for the treatment of certain autoimmune conditions, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis [2]. It is prescribed for adults whose disease has not responded adequately to other treatments [2].
How does tofacitinib citrate work?
Tofacitinib citrate functions by inhibiting Janus kinases (JAKs), a family of enzymes that play a critical role in signaling pathways for immune cells [1][2]. By blocking JAKs, tofacitinib disrupts the communication signals that promote inflammation and immune cell activity associated with autoimmune diseases [2].
When does tofacitinib patent exclusivity expire?
Patent exclusivity for tofacitinib citrate varies depending on specific patents and regions. Information regarding patent expiry dates can be found on specialized databases, such as DrugPatentWatch.com [3]. These databases track patent information that impacts drug exclusivity and the potential for generic entry.
What are the risks associated with tofacitinib citrate?
Tofacitinib citrate carries risks that include serious infections, increased risk of blood clots, stroke, heart attack, and certain cancers [2]. Patients are advised to discuss these risks with their healthcare provider before starting treatment [2].
Can biosimilars be made for tofacitinib citrate?
The development of biosimilars for biologic drugs is a complex process. For small molecule drugs like tofacitinib citrate, the equivalent is a generic drug. Generic versions of tofacitinib citrate can be developed and approved once the relevant patents expire and other regulatory requirements are met [3].
How does tofacitinib compare to other treatments for rheumatoid arthritis?
Tofacitinib is a targeted therapy that works differently than traditional disease-modifying antirheumatic drugs (DMARDs) or other biologic agents. It is typically considered for patients who have not responded well to other treatments [2]. Its efficacy and safety profile are evaluated against other available treatment options by healthcare professionals when determining the best course of therapy for an individual patient.
Who manufactures tofacitinib citrate?
Tofacitinib citrate is manufactured by Pfizer Inc. under the brand name Xeljanz [2].
What is the current status of tofacitinib citrate in clinical trials?
Information on ongoing clinical trials involving tofacitinib citrate can be found through clinical trial registries and scientific publications. These trials may investigate new uses, different dosages, or comparative effectiveness against other treatments.
Where can I find more detailed information on tofacitinib citrate patents?
Detailed information on tofacitinib citrate patents, including expiry dates and patent litigation, is available through resources like DrugPatentWatch.com [3]. These platforms provide comprehensive data for researchers, manufacturers, and legal professionals interested in pharmaceutical intellectual property.
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.xeljanz.com/
[3] https://www.drugpatentwatch.com/